Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

ClinicalTrials.gov ID: NCT05879367

Public ClinicalTrials.gov record NCT05879367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Study identification

NCT ID: NCT05879367
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Orbus Therapeutics, Inc.; Industry
Enrollment: 66 participants

Conditions and interventions

Conditions

Interventions

Eflornithine (Dose Level -1) Drug
Eflornithine (Dose Level 2) Drug
Temozolomide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 23, 2023
Primary completion: Jun 29, 2026
Completion: Jun 29, 2026
Last update posted: Jun 24, 2025

2023 – 2026

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Withdrawn
Henry Ford Hospital	Detroit	Michigan	48202	Recruiting
Columbia University Medical Center - Herbert Irving Pavilion	New York	New York	10032	Recruiting
Duke University	Durham	North Carolina	27710	Recruiting
The Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
Brown University Health/Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
UT MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05879367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 24, 2025 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05879367 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →